Dicerna Pharma (DRNA) Reports In-Line Q4 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Dicerna Pharmaceuticals (DRNA) PT Lifted to $40 at Leerink Partners Post Q4
March 13, 2015 7:43 AM EDTLeerink Partners analyst Michael Schmidt reiterated an Outperform rating and boosted his price target on Dicerna Pharmaceuticals (NASDAQ: DRNA) to $40.00 (from $25.00) following 4Q14 financial results and a pipeline update.
Schmidt commented, "DRNA reported 4Q14 financial results and provided a pipeline update. Two... More
Dicerna Pharma (DRNA) Fils 10.7M Common Shelf for Shareholders; $50M Mixed Shelf
March 12, 2015 4:48 PM EDTDicerna Pharma (NASDAQ: DRNA) filed to sell up to 10,687,733 shares of Common Stock on behalf of Selling Stockholders, 10 million shares of common stock, and $50 million of mixed securities.
... More